Eiger BioPharmaceuticals, Inc. Stock price
Equities
EIGR
US28249U2042
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.005 USD | +0.50% | -16.02% | -25.69% |
Financials (USD)
Sales 2023 * | 18.45M | Sales 2024 * | 25.22M | Capitalization | 7.37M |
---|---|---|---|---|---|
Net income 2023 * | -72M | Net income 2024 * | -24M | EV / Sales 2023 * | 0.4 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 0.29 x |
P/E ratio 2023 * |
-0.1
x | P/E ratio 2024 * |
-0.32
x | Employees | 56 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 88.2% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | +0.50% | ||
1 week | -16.02% | ||
Current month | -10.62% | ||
1 month | -13.57% | ||
3 months | -37.33% | ||
6 months | -44.76% | ||
Current year | -25.69% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Director of Finance/CFO | 58 | 23-04-12 | |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 17 M€ | +5.91% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.005 | +0.50% | 3 229 |
24-03-27 | 4.98 | -7.18% | 4,748 |
24-03-26 | 5.365 | -4.03% | 20,165 |
24-03-25 | 5.59 | -2.95% | 7,549 |
24-03-22 | 5.76 | -3.36% | 13,310 |
Delayed Quote Nasdaq, March 28, 2024 at 01:54 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.69% | 7.37M | |
+9.39% | 45.97B | |
+52.73% | 43.93B | |
+7.54% | 42.34B | |
-8.78% | 28.27B | |
+18.56% | 27.18B | |
-21.98% | 19.44B | |
+14.82% | 13.83B | |
+32.02% | 12.4B | |
+5.83% | 11.45B |